



**Section I. (The Claims)**

1. (Currently Amended) A compound having ~~general~~ formula I:



where















- $Q^-$  represents the conjugate base of a pharmaceutically suitable organic or inorganic acid;
- $R_1$  and  $R'_1$  represent, independently of each other, a radical selected from the group formed by H and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl or alkoxy;
- $R_2$  and  $R'_2$  represent, independently of each other, an aryl radical ~~optionally~~ substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy;
- $R_3$  and  $R'_3$  represent, independently of each other, either a radical selected from the group formed by H, halogen, trifluoromethyl, hydroxyl, amino, alkoxy and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl, amino or alkoxy, or together with  $R_4$  and  $R'_4$  respectively, and independently of each other, a  $-CH=CH-CH=CH-$  radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy;
- $R_4$  and  $R'_4$  represent, independently of each other, either a radical selected from the group formed by H and  $C_{1-6}$  alkyl optionally substituted by halogen, trifluoromethyl, hydroxyl, amino or alkoxy, or together with  $R_3$  and  $R'_3$  respectively, and independently of each other, a  $-CH=CH-CH=CH-$  radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy; and
- A represents a spacer group having the following formula:









wherein m, n and p represent integers which can have the following values: m = 1; n = 0, 1-10; p = 0, 1; with the condition that m, n and p do not take the value of zero at the same time.

2. (Cancelled)

3. (Currently Amended) A compound according to claim 1, ~~characterized in that~~ wherein  $R_2$  and  $R'_2$  represent, independently of each other, a phenyl radical ~~optionally~~ substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino and alkoxy.
4. (Currently Amended) A compound according to claim 3, ~~characterized in that~~ wherein  $R_1$  and  $R'_1$  represent a methyl radical, and in that  $R_2$  and  $R'_2$  represent, independently of each other, a phenyl radical ~~optionally~~ substituted by one or more halogen substituents.
5. (Currently Amended) A compound according to claim 1, ~~characterized in that~~ wherein both  $R_3$  and  $R_4$  and  $R'_3$  and  $R'_4$  together represent, although independently of each other, a  $-CH=CH-CH=CH-$  radical optionally substituted by one or more halogen substituents.
6. (Currently Amended) A compound according to claim 1, ~~characterized in that~~ wherein it has the following substituents:

No.	$(R_3, R_4)$ and $(R'_3, R'_4)$	$NR_1R_2$ and $NR'_1R'_2$	A	Code
1	H, H			ACG560B
2	H, H			ACG416B
3	H, H			ACG548B
4	H, H			ACG604A
5	$-(CH=CH)_2-$			RSM964A
6	$-C^5H=C^6H-$ $C^7Cl=C^8H-$			RSM820C
7	$-(CH=CH)_2-$			

				RSM932A
8	$-C^5H=C^6H-$ $C^7Cl=C^8H-$			RSM824B
9	$-(CH=CH)_2-$			RSM936A
10	$-C^5H=C^6H-$ $C^7Cl=C^8H-$			RSM828B

7. (Currently Amended) A compound according to claim 6, ~~characterized in that~~ wherein Q represents Br (bromide) or F<sub>6</sub>P (hexafluorophosphate).

8. (Currently Amended) A pharmaceutical ~~formulation~~ composition comprising at least one compound defined in claim 1 as an active ingredient.

9. (Cancelled)

10. (Cancelled)


11. (Cancelled)

12. (Cancelled)

13. (Currently Amended) A process for preparing a compound according to claim 1 comprising reacting:

- a) the corresponding heterocyclic ~~derivative~~ compound of formula VII and the dihalogenated ~~derivative~~ compound AX<sub>2</sub> (where X represents the halogen atom: Cl, Br or I) in 2:1 molar amounts in an organic solvent or,
- b) the corresponding heterocyclic ~~derivative~~ compound of formula VII and the dihalogenated ~~derivative~~ compound AX<sub>2</sub> (where X represents the halogen atom: Cl, Br or I) in a 1:1 molar ratio in an organic solvent, in order to give a monoquaternized product which is again reacted with another different heterocyclic ~~derivative~~ molecule, in a 1:1 molar ratio, using an organic solvent that is more polar than the first one,

wherein the compound having ~~general~~ formula VII is characterized by



VII

where

$R_1$  represents a radical selected from the group formed by H and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl or alkoxy;


$R_2$  represents an aryl radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy

$R_3$  represents either a radical selected from the group formed by H, halogen, trifluoromethyl, hydroxyl, amino, alkoxy and  $C_{1-6}$  alkyl optionally substituted by trifluoromethyl, hydroxyl, amino or alkoxy, or together with  $R_4$  a  $-CH=CH-CH=CH-$  radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy;

$R_4$  represents either a radical selected from the group formed by H, and  $C_{1-6}$  alkyl optionally substituted by halogen, trifluoromethyl, hydroxyl, amino or alkoxy, or together with  $R_3$  a  $-CH=CH-CH=CH-$  radical optionally substituted by halogen, trifluoromethyl, hydroxyl,  $C_{1-6}$  alkyl, amino or alkoxy.


14. (Cancelled)

15. (Currently Amended) ~~Compounds~~ The compound according to claim 13 having formulas:  
4-(4-chloro-*N*-methylanilino)quinoline



VIII A

and 7-chloro-4-(4-chloro-*N*-methylanilino)quinoline



VIII B.

16. (Withdrawn) Method for treating breast, lung, colorectal and/or pancreatic cancer in a patient in need of such treatment, said method comprising administering a compound according to claim 1.
17. (Withdrawn) Method for an antiviral, antiparasitic and/or antifungal treatment in a patient in need of such treatment, said method comprising administering a compound according to claim 1.
18. (New) A compound according to claim 1, wherein it has the following substituents:



No.	(R <sub>3</sub> , R <sub>4</sub> ) and (R' <sub>3</sub> , R' <sub>4</sub> )	NR <sub>1</sub> R <sub>2</sub> and NR' <sub>1</sub> R' <sub>2</sub>	A	Code
5	-(CH=CH) <sub>2</sub> -			RSM964A

19. (New) A compound according to claim 1, wherein it has the following substituents:



No.	(R <sub>3</sub> , R <sub>4</sub> ) and (R' <sub>3</sub> , R' <sub>4</sub> )	NR <sub>1</sub> R <sub>2</sub> and NR' <sub>1</sub> R' <sub>2</sub>	A	Code
6	-C <sup>5</sup> H=C <sup>6</sup> H- C <sup>7</sup> Cl=C <sup>8</sup> H-			RSM820C

20. (New) A compound according to claim 1, wherein it has the following substituents:

No.	(R <sub>3</sub> , R <sub>4</sub> ) and (R' <sub>3</sub> , R' <sub>4</sub> )	NR <sub>1</sub> R <sub>2</sub> and NR' <sub>1</sub> R' <sub>2</sub>	A	Code
-----	---	---	---	------

7	$-(\text{CH}=\text{CH})_2-$			RSM932A
---	-----------------------------	--	---	---------

21. (New) A compound according to claim 1, wherein it has the following substituents:

No.	$(\text{R}_3, \text{R}_4)$ and $(\text{R}'_3, \text{R}'_4)$	$\text{NR}_1\text{R}_2$ and $\text{NR}'_1\text{R}'_2$	A	Code
10	$-\text{C}^5\text{H}=\text{C}^6\text{H}-$ $\text{C}^7\text{Cl}=\text{C}^8\text{H}-$			RSM828B